Intellia Therapeutics (NASDAQ:NTLA) Receives “Buy” Rating from Canaccord Genuity Group

Canaccord Genuity Group restated their buy rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report issued on Thursday morning, Benzinga reports. Canaccord Genuity Group currently has a $73.00 target price on the stock.

Other equities research analysts have also issued research reports about the company. StockNews.com raised Intellia Therapeutics to a sell rating in a report on Thursday. Citigroup lowered their price objective on Intellia Therapeutics from $31.00 to $29.00 and set a neutral rating on the stock in a report on Friday, May 10th. Cantor Fitzgerald reissued an overweight rating and set a $65.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 24th. Truist Financial reissued a buy rating and set a $120.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 24th. Finally, Wedbush reissued a neutral rating and set a $29.00 price target on shares of Intellia Therapeutics in a research note on Tuesday, April 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $69.00.

Intellia Therapeutics Trading Down 3.5 %

Shares of NTLA opened at $22.38 on Thursday. Intellia Therapeutics has a twelve month low of $19.37 and a twelve month high of $46.50. The stock’s 50 day moving average is $23.76 and its two-hundred day moving average is $26.28. The firm has a market capitalization of $2.16 billion, a PE ratio of -4.18 and a beta of 1.84.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.29. Intellia Therapeutics had a negative return on equity of 45.35% and a negative net margin of 893.34%. The company had revenue of $28.94 million for the quarter, compared to analyst estimates of $15.60 million. On average, sell-side analysts predict that Intellia Therapeutics will post -4.98 EPS for the current year.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. purchased a new position in shares of Intellia Therapeutics during the 4th quarter worth $26,000. Signaturefd LLC lifted its stake in shares of Intellia Therapeutics by 89.3% during the 4th quarter. Signaturefd LLC now owns 1,592 shares of the company’s stock worth $49,000 after purchasing an additional 751 shares during the period. Daiwa Securities Group Inc. lifted its stake in shares of Intellia Therapeutics by 35.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,056 shares of the company’s stock worth $93,000 after purchasing an additional 793 shares during the period. EntryPoint Capital LLC lifted its stake in shares of Intellia Therapeutics by 61.1% during the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock worth $113,000 after purchasing an additional 1,563 shares during the period. Finally, Spire Wealth Management lifted its stake in shares of Intellia Therapeutics by 3,789.0% during the 4th quarter. Spire Wealth Management now owns 3,889 shares of the company’s stock worth $119,000 after purchasing an additional 3,789 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.